CD1.129-Ccr6^tm1Gma/Cnbc

Status	Available to order
EMMA ID	EM:06068
Citation information	RRID:IMSR_EM:06068 Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information.
International strain name	CD1.129-Ccr6^tm1Gma/Cnbc
Alternative name	CD1.129-Ccr6 tm1/Gma
Strain type	Targeted Mutant Strains : Knock-out
Allele/Transgene symbol	Ccr6^tm1Gma
Gene/Transgene symbol	Ccr6

Information from provider

Provider	Rosa Varona
Provider affiliation	Centro Nacional de Biotecnologia (CNB-CSIC)
Genetic information	A PGK-neomycin resistance cassette replaced most of the coding exon, leaving the sequences that encode the 25 carboxy terminal amino acids. Northern analysis of spleen and thymus did not detect mRNA in homozygous mutant mice. Mutant mice backcrossed to CD1 more than 9 generations.
Phenotypic information	Ccr6-deficient mice have underdeveloped Peyer's patches, impaired leukocyte homeostasis and altered contact hypersensitivity and delayed-type hypersensitivity responses.
Breeding history	The original mutant strain was backcrossed to CD1 genetic background more than 9 generations.
References	CCR6-deficient mice have impaired leukocyte homeostasis and altered contact hypersensitivity and delayed-type hypersensitivity responses.;Varona R, Villares R, Carramolino L, Goya I, Zaballos A, Gutiérrez J, Torres M, Martínez-A C, Márquez G, ;2001;The Journal of clinical investigation;107;R37-45; 11254677 CCR6 has a non-redundant role in the development of inflammatory bowel disease.;Varona Rosa, Cadenas Vanesa, Flores Juana, Martínez-A Carlos, Márquez Gabriel, ;2003;European journal of immunology;33;2937-46; 14515278 CCR6 regulates CD4+ T-cell-mediated acute graft-versus-host disease responses.;Varona Rosa, Cadenas Vanesa, Gómez Lucio, Martínez-A Carlos, Márquez Gabriel, ;2005;Blood;106;18-26; 15774622 CCR6 regulates the function of alloreactive and regulatory CD4+ T cells during acute graft-versus-host disease.;Varona Rosa, Cadenas Vanesa, Lozano María, Moreno-Ortiz Maria Carmen, Kremer Leonor, Martínez-A Carlos, Márquez Gabriel, ;2006;Leukemia & lymphoma;47;1469-76; 16966255 Protective immunity and delayed type hypersensitivity reaction are uncoupled in experimental Leishmania major infection of CCR6-negative mice.;Lechner Anja, Ritter Uwe, Varona Rosa, Marquez Gabriel, Bogdan Christian, Körner Heinrich, ;2007;Microbes and infection;9;291-9; 17317260 CCR6 regulates EAE pathogenesis by controlling regulatory CD4+ T-cell recruitment to target tissues.;Villares Ricardo, Cadenas Vanessa, Lozano María, Almonacid Luis, Zaballos Angel, Martínez-A Carlos, Varona Rosa, ;2009;European journal of immunology;39;1671-81; 19499521
Homozygous fertile	yes
Homozygous viable	yes
Homozygous matings required	yes
Immunocompromised	no

Information from EMMA

Archiving centre	CNB-CSIC, Centro Nacional de Biotecnologia, Madrid, Spain
Animals used for archiving	homozygous CD-1 outbred stock (syn.: outbr. CD-1 or CD1, Swiss CD-1 or CD1, ICR(CD-1), etc.) males, wild-type CD-1 outbred stock (syn.: outbr. CD-1 or CD1, Swiss CD-1 or CD1, ICR(CD-1), etc.) females
Stage of embryos	4/8-cell

Disease and phenotype information

IMPC phenotypes (gene matching)

hyperactivity / IMPC
abnormal spleen morphology / IMPC
decreased heart rate / IMPC
prolonged RR interval / IMPC

MGI phenotypes (allele matching)

increased leukocyte cell number / MGI
decreased leukocyte cell number / MGI
abnormal Peyer's patch morphology / MGI
decreased inflammatory response / MGI
abnormal Peyer's patch follicle morphology / MGI
abnormal CD4-positive, alpha-beta T cell physiology / MGI
abnormal myeloid dendritic cell morphology / MGI

MGI phenotypes (gene matching)

increased leukocyte cell number / MGI
decreased leukocyte cell number / MGI
abnormal Peyer's patch morphology / MGI
abnormal choroid plexus morphology / MGI
decreased IgA level / MGI
increased activated T cell number / MGI
decreased inflammatory response / MGI
no abnormal phenotype detected / MGI
abnormal dendritic cell physiology / MGI
abnormal gut-associated lymphoid tissue morphology / MGI
abnormal Peyer's patch follicle morphology / MGI
abnormal Peyer's patch germinal center morphology / MGI
abnormal Peyer's patch T cell area morphology / MGI
decreased susceptibility to bacterial infection / MGI
increased susceptibility to viral infection / MGI
abnormal CD4-positive, alpha beta T cell morphology / MGI
abnormal T cell physiology / MGI
abnormal macrophage physiology / MGI
abnormal B cell physiology / MGI
decreased IgE level / MGI
increased IgM level / MGI
abnormal lymphocyte morphology / MGI
decreased susceptibility to experimental autoimmune encephalomyelitis / MGI
increased B-1 B cell number / MGI
increased T cell number / MGI
decreased B cell number / MGI
increased double-positive T cell number / MGI
increased T cell proliferation / MGI
abnormal CD4-positive, alpha-beta T cell physiology / MGI
decreased susceptibility to type I hypersensitivity reaction / MGI
abnormal myeloid dendritic cell morphology / MGI
decreased CD4-positive, alpha beta T cell number / MGI
decreased CD8-positive, alpha-beta T cell number / MGI
decreased Peyer's patch number / MGI
abnormal follicular dendritic cell physiology / MGI
abnormal follicular dendritic cell antigen presentation / MGI
abnormal peritoneal macrophage morphology / MGI
abnormal alpha-beta intraepithelial T cell morphology / MGI
abnormal CD4-positive, alpha-beta intraepithelial T cell morphology / MGI
abnormal CD8 positive, alpha-beta intraepithelial T cell morphology / MGI
decreased IgG3 level / MGI
decreased tumor necrosis factor secretion / MGI
increased interferon-gamma secretion / MGI
abnormal interleukin secretion / MGI
decreased interleukin-10 secretion / MGI
decreased interleukin-12 secretion / MGI
decreased interleukin-4 secretion / MGI
decreased interleukin-5 secretion / MGI
impaired eosinophil recruitment / MGI
abnormal intraepithelial T cell number / MGI
decreased macrophage nitric oxide production / MGI
decreased macrophage cytokine production / MGI

Literature references

CCR6-deficient mice have impaired leukocyte homeostasis and altered contact hypersensitivity and delayed-type hypersensitivity responses.;Varona R, Villares R, Carramolino L, Goya I, Zaballos A, Gutiérrez J, Torres M, Martínez-A C, Márquez G, ;2001;The Journal of clinical investigation;107;R37-45; 11254677
CCR6 has a non-redundant role in the development of inflammatory bowel disease.;Varona Rosa, Cadenas Vanesa, Flores Juana, Martínez-A Carlos, Márquez Gabriel, ;2003;European journal of immunology;33;2937-46; 14515278
CCR6 regulates CD4+ T-cell-mediated acute graft-versus-host disease responses.;Varona Rosa, Cadenas Vanesa, Gómez Lucio, Martínez-A Carlos, Márquez Gabriel, ;2005;Blood;106;18-26; 15774622
CCR6 regulates the function of alloreactive and regulatory CD4+ T cells during acute graft-versus-host disease.;Varona Rosa, Cadenas Vanesa, Lozano María, Moreno-Ortiz Maria Carmen, Kremer Leonor, Martínez-A Carlos, Márquez Gabriel, ;2006;Leukemia & lymphoma;47;1469-76; 16966255
Protective immunity and delayed type hypersensitivity reaction are uncoupled in experimental Leishmania major infection of CCR6-negative mice.;Lechner Anja, Ritter Uwe, Varona Rosa, Marquez Gabriel, Bogdan Christian, Körner Heinrich, ;2007;Microbes and infection;9;291-9; 17317260
CCR6 regulates EAE pathogenesis by controlling regulatory CD4+ T-cell recruitment to target tissues.;Villares Ricardo, Cadenas Vanessa, Lozano María, Almonacid Luis, Zaballos Angel, Martínez-A Carlos, Varona Rosa, ;2009;European journal of immunology;39;1671-81; 19499521

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

Frozen embryos. Delivered in 4 weeks (after paperwork in place). €1740^*
Frozen sperm. Delivered in 4 weeks (after paperwork in place). €1740^*
Rederivation of mice from frozen stock, delivery time available upon request . €3880^*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

^* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Genotyping protocol

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
Distribution of this strain is subject to a provider MTA. Both signing of the MTA and submission of the online EMMA Mutant Request Form are required before material can be shipped.

EMMA conditions
Legally binding conditions for the transfer

Right strain for your research?

The information provided on this page is, to the best of EMMA’s knowledge, based on data supplied by the original provider. End users are responsible for reviewing these details and for validating the strain and its suitability for their experimental use.
Not found what you were looking for? Search here for other strains available from EMMA.

CD1.129-Ccr6tm1Gma/Cnbc